Zacks Investment Research downgraded shares of ARATANA THERAP (PETX) from OUTPERFORM to NEUTRAL on April 14, 2014, with a target price of $18.40.
Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ARATANA THERAP (PETX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment